PiaSchulzzurwiesch25.jpg

Flag icon Flag icon
Researcher

Pia Abel zur Wiesch

Researcher
Computational Pharmacology, Research Group

Job description:

Young Associate Investigator, NCMM, Nordic EMBL partnership

Seniorforsker (Associate Professor, tenure track), Institute for Pharmacy, UiT




Research interests

Antibiotics, Population Biology, Biochemistry, Pharmacology, Tuberculosis, Infectious Diseases,Public Health, Mathematical Modelling

Publications in CRIStin


  • Martinecz, Antal; Abel zur Wiesch, Pia. Estimating treatment prolongation for persistent infections. Pathogens and Disease 2018; Volum 76 (6). ISSN 2049-632X.s doi: 10.1093/femspd/fty065.

  • Abel zur Wiesch, Pia; Clarelli, Fabrizio; Cohen, Ted. Using chemical reaction kinetics to predict optimal antibiotic treatment strategies. PloS Computational Biology 2017; Volum 13:e1005321 (1). ISSN 1553-734X.s 1 - 28.s doi: 10.1371/journal.pcbi.1005321.

  • Zhang, Ting; Abel, Sören; Abel zur Wiesch, Pia; Sasabe, Jumpei; Davis, Brigid M.; Higgins, Darren E.; Waldor, Matthew K.. Deciphering the landscape of host barriers to Listeria monocytogenes infection. Proceedings of the National Academy of Sciences of the United States of America 2017; Volum 114 (24). ISSN 0027-8424.s 6334 - 6339.s doi: 10.1073/pnas.1702077114.

  • Cadosch, Dominique; Abel zur Wiesch, Pia; Kouyos, Roger; Bonhoeffer, Sebastian. The Role of Adherence and Retreatment in De Novo Emergence of MDR-TB. PloS Computational Biology 2016; Volum 12 (3). ISSN 1553-734X.s doi: 10.1371/journal.pcbi.1004749.

  • Kunkel, Amber; Abel zur Wiesch, Pia; Nathavitharana, Ruvandhi R.; Marx, Florian M.; Jenkins, Helen E.; Cohen, Ted. Smear positivity in paediatric and adult tuberculosis: systematic review and meta-analysis. BMC Infectious Diseases 2016; Volum 16 (282). ISSN 1471-2334.s 1 - 9.s doi: 10.1186/s12879-016-1617-9.

  • Hubbard, Troy; Chao, Michael C; Abel, Sören; Blondel, Carlos J; Abel zur Wiesch, Pia; Zhou, Xiaohui; Davis, Brigid M.; Waldor, Matthew K.. Genetic analysis of vibrio parahaemolyticus intestinal colonization. Proceedings of the National Academy of Sciences of the United States of America 2016; Volum 113 (22). ISSN 0027-8424.s 6283 - 6288.s doi: 10.1073/pnas.1601718113.

  • Abel zur Wiesch, Pia; Abel, Sören; Gkotzis, Spyridon; Ocampo, Paolo; Engelstädter, Jan; Hinkley, Trevor; Magnus, Carsten; Waldor, Matthew K.; Udekwu, Klas; Cohen, Ted. Classic reaction kinetics can explain complex patterns of antibiotic action. Science Translational Medicine 2015; Volum 7 (287). ISSN 1946-6234.s doi: 10.1126/scitranslmed.aaa8760.

  • Abel, Sören; Schulz Zur Wiesch, Pia; Davis, Brigid M.; Waldor, Matthew K.. Analysis of Bottlenecks in Experimental Models of Infection. PLoS Pathogens 2015; Volum 11:e1004823 (6). ISSN 1553-7366.s doi: 10.1371/journal.ppat.1004823.

  • Martinecz, Antal; Boeree, Martin J.; Diacon, Andreas H.; Dawson, Rodney; Aarnoutse, Rob E.; Abel zur Wiesch, Pia. High peak drug concentrations increase the bactericidal action in the slow phase of bacterial elimination in EBA trials of tuberculosis patients. Conference presentation at "2nd Arctic Meeting on Clinical Tuberculosis". 2nd Arctic Meeting on Clinical Tuberculosis 2019-02-22 - 2019.

  • Clarelli, Fabrizio; Singh, Bhupender; Palmer, Adam; Abel, Sören; Cohen, Ted; Abel zur Wiesch, Pia. Quantitatively predicting antibiotic susceptibility from biochemical parameters: implications for antibiotic development and preventing resistance. 11th edition of the International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018-10-23 - 2018-10-23 2018.

  • Martinecz, Antal; Boeree, Martin J.; Diacon, Andreas H.; Dawson, Rodney; Aarnoutse, Rob E.; Abel zur Wiesch, Pia. High peak drug concentrations increase the bactericidal action in the slow phase of bacterial elimination in EBA trials of tuberculosis patients. Conference presentation at "International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018" The Hague, Netherlands. International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018 2018-10-23 - 2018.

  • Clarelli, Fabrizio; Singh, Bhupender; Cohen, Ted; Palmer, Adam; Chindelevitch, Leonid; Abel, Sören; Abel zur Wiesch, Pia. Using models to understand how molecular mechanisms of resistance affect the risk of acquired drug resistance during treatment. International Study Group for Systems Biology (ISGSB) Conference 2018-09-24 - 2018-09-28 2018.

  • Clarelli, Fabrizio; Cohen, Ted; Abel, Sören; Singh, Bhupender; Palmer, Adam; Chindelevitch, Leonid; Abel zur Wiesch, Pia. How molecular mechanisms of resistance affect resistance evolution. Challenges and new concepts in antibiotics research conference 2018-03-19 - 2018-03-21 2018.

  • Martinecz, Antal; Abel zur Wiesch, Pia; Regoes, Roland R.. Within Host Infection Dynamics: Persisters can infect new sites and cause relapse if the immune clearance is low. Conference "Challenges and new concepts in antibiotics research”, Institute Pasteur, Paris, France 2018-03-19 - 2018-03-21 2018.

  • Clarelli, Fabrizio; Chindelevitch, Leonid; Singh, Bhupender; Cohen, Ted; Abel, Sören; Abel zur Wiesch, Pia. Using models to understand how molecular mechanisms of resistance affect the risk of acquired drug resistance during treatment. Epidemics 6 Sixth International Conference on Infectious Disease Dynamics 2017-11-29 - 2017-12-01 2017.

  • Abel zur Wiesch, Pia; Cohen, Ted; Mostowy, Rafał; Shams, Alireza. Predicting Antibiotic Pharmacodynamics Using Chemical Kinetics. (data) (fulltekst) 2017.

  • Publications outside Cristin

    A Kunkel*, P Abel zur Wiesch*, RR Nathavitharana, FM Marx, HE Jenkins, T Cohen

    BMC infectious diseases 16 (1), 282

    Hubbard PT, Chao MC, Abel S, Blondel CJ, Abel zur Wiesch P, Zhou X, Davis BM, and Waldor MK.
    PNAS (2016) published ahead of print doi:10.1073/pnas.1601718113.

    Cadosch D, Abel zur Wiesch P, Kouyos RD, and Bonhoeffer, S.
    PLOS Computational Biology (2016) 12 (3):e1004749.

    Salvatore P, Becerra M, Abel zur Wiesch P, Hinkley T, Kaur D, Sloutsky A, Cohen T
    Fitness costs of drug-resistance mutations in multidrug resistant M. tuberculosis: a household-based case-control study.
    J. Infect. Dis. (2015) pii: jiv347. [Epub ahead of print]

    Abel S, Abel zur Wiesch P, Davis BM, and Waldor MK
    Analysis of bottlenecks in experimental models of infection.
    PLOS PATHOGENS (2015) 11(6):e1004823

    Abel zur Wiesch P#, Abel S, Gkotzis S, Ocampo P, Engelstädter J, Hinkley T, Magnus C, Waldor MK, Udekwu K, and Cohen T
    Classic reaction kinetics can explain complex patterns of antibiotic action.
    SCI. TRANSL. MED. (2015) 7(287):287ra73    

    Abel S, Abel zur Wiesch P, Chang H-H, Davis BM, Lipsitch M, and Waldor MK
    Sequence tag-based analysis of pathogen population dynamics.
    Nature Methods (2015) 12(3):223-6

    Kouyos RD, Metcalf CJE, Birger R, Klein EY, Abel zur Wiesch P, Ankomah P, et al.
    The path of least resistance: aggressive or moderate treatment?
    Proceedings of the Royal Society B: Biological Sciences (2014) 281(1794):20140566

    Ocampo PS, Lazar V, Bogos B, Arnoldini M, Abel zur Wiesch P, Busa-Fekete R, Fekete G, Pal C, Ackermann M and Bonhoeffer S
    Antagonism is prevalent between bacteriostatic and bactericidal antibiotics.
    Antimicrobial Agents and Chemotherapy (2014) 58(8):4573-82

    Abel zur Wiesch P#*, Kouyos RD*, Abel S, Viechtbauer W, and Bonhoeffer S
    Optimal antibiotic treatment in hospitals: meta-analysis and models.
    PLOS Pathogens (2014) 10(6):e1004225

    Abel S, Bucher T, Nicollier M, Hug I, Kaever V, Abel zur Wiesch P, Jenal U
    Bi-modal Distribution of the Second Messenger c-di-GMP Controls Cell Fate and Asymmetry during the Caulobacter Cell Cycle.
    PLOS Genetics (2013) 9(9):e1003744

    Kouyos RD*, Abel zur Wiesch P*, Bonhoeffer S
    On being the right size: the impact of population size and stochastic effects on the evolution of drug resistance in hospitals and the community.
    PLOS Pathogens (2011) 7(4):e1001334.

    Kouyos RD, Abel zur Wiesch P, Bonhoeffer S
    Informed Switching Strongly Decreases the Prevalence of Antibiotic Resistance in Hospital Wards.
    PLOS Computational Biology (2011) 7(3):e1001094.

    Abel zur Wiesch P*, Kouyos R*, Engelstädter J, Regoes R, Bonhoeffer S
    Population biological principles of resistance evolution in infectious diseases.
    Lancet Infectious Diseases (2011) 11(3):236-247.

    Bonhoeffer S, Abel zur Wiesch P, and Kouyos RD
    Rotating antibiotics does not minimize selection for resistance.
    Mathematical Biosciences and Engineering (2010) 7(4):919-922.

    Schulz zur Wiesch P#, Engelstädter J, and Bonhoeffer S
    Compensation of Fitness Costs and Reversibility of Antibiotic Resistance Mutations.
    Antimicrobial Agents and Chemotherapy (2010) 54(5):2085-95

    Member of research group